期刊文献+

地西他滨单药或联合预激方案治疗骨髓增生异常综合征及急性髓系白血病的临床分析 被引量:21

Clinical observation of decitabine alone or in combination with pre- excitation regimen in treatment for patients with myelodysplastic syndrome or acute myeloid leukemia
收藏 分享 导出
摘要 目的:探讨地西他滨单药或联合预激方案治疗骨髓增生异常综合征(myelodysplastic syndrome,MDS)/急性髓系白血病(acute myeloid leukemia,AML)的临床疗效及安全性。方法 :回顾性分析18例MDS/AML患者接受地西他滨单药或联合预激方案治疗的临床疗效及不良反应。结果 :18例患者中,12达完全缓解,2例达骨髓完全缓解,总有效率为77.8%(14/18)。15例并发感染(83.3%,15/18);1例化疗后死亡,化疗相关死亡率为5.6%(1/18)。结论 :地西他滨单药或联合预激方案治疗MDS/AML的缓解率较高,不良反应可耐受。 Objective:To evaluate the therapeutic efficacy and safty of decitabine alone or in combination with pre-excitation regimen in the treatment for patients with myelodysplastic syndrome(MDS)/acute myeloid leukemia(AML).Methods:The therapeutic efficacy and safty of decitabine alone or in combination with pre-excitation regimen in the treatment for 18 patients with MDS/AML were retrospectively analyzed.Results:Of the 1 8 patients,1 2 patients achieved complete remission,2 patients achieved marrow complete remission,and the overall response rate was 77.8%(14/18).The infection emerged in 15patients(83.3%,15/18);only one patient died of chemotherapy-related infection(5.6%,1 /18).Conclusion:The remission rate of patients with MDS/AML receiving decitabine alone or in combination with pre-excitation regimen was high,and the adverse effects can be accepted.
作者 邢丽娜 任金海 蔡圣鑫 张晓蕾 郭晓玲 郭晓楠 XlNG Li-na, REN Jin-hai, CAI Sheng-xin, ZHANG Xiao-lei, GUO Xiao-ling, GUO Xiao-nan (Department of Hematology, Second Affiliated Hospital, Hebei Medical University, Shijiazhuang 050000, Hebei Province, China)
出处 《肿瘤》 CAS CSCD 北大核心 2015年第5期544-549,591共7页 Tumor
关键词 白血病 髓性 骨髓增生异常综合征 地西他滨 Leukemia myeloid Myelodysplastic syndrome Decitabine
  • 相关文献

参考文献21

  • 1中华医学会血液学分会.骨髓增生异常综合征诊断与治疗中国专家共识(2014年版)[J].中华血液学杂志,2014,35(11):1042-1048. 被引量:128
  • 2成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2011年版)[J].中华血液学杂志,2011,32(11):804-807. 被引量:95
  • 3Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J]. Blood, 2006, 108(2):419-425. 被引量:1
  • 4Cheson BD, Bennett JM, Kopecky I/J, eta/. Revised recommoendations of the International Working Group (IWG) for diagnosis, standardization of response criteria,treatment outcomes,and reporting standards for therapeutic traials in acute myeloid leukemia[J].J C/in Oncol, 2003, 21 (24):4642-4649. 被引量:1
  • 5Miller AB, Hoogstraten B, Staquet M, et a/. Reporting results of cancer treatment[J]. Cancer, 1981, 47(1), 207-214. 被引量:1
  • 6Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in rnyelodysplastic syndromes: Results of a phase ]II randomized study[J]. Cancer, 2006, 106(8):1794-1803. 被引量:1
  • 7Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomrized study of 3 schedules of low- dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J]. Blood, 2007, 109(1):52-57. 被引量:1
  • 8Cashen A, Schiller G, Larsen JS, et al. Phase II study of low-dose decitabine for the frist-line treatment of older patients with acute myeloid leukemia (AML)[J]. J Clin Oncol, 2010, 28(4):556-$61. 被引量:1
  • 9Yamada K, Furusawas S, Saito K, et a/. Concurrent use of granulocyte colony-stimulating factor with low- dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: apilot study[J]. Leukemia, 1995, 9(1 ):10-14. 被引量:1
  • 10Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines[J]. Clin Cancer Res, 2007, 131 (4):4225-4232. 被引量:1

二级参考文献13

  • 1Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open- label, phase Ⅲ trial of decitabine versus patient choice, with physician advice, of either supportive care or low- dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia [J]. J Clin Oncol, 2012, 30(21 ):2670-2677. 被引量:1
  • 2Yamada K, Furusawa S, Saito K, et al. Concttrrent use of granu- locyte colony-stimulating factor with low-dose cytosine arabino- side and aclarubicin for previously treated acute myelogenous leukemia: a pilot study[J]. Leukemia,1995, 9 ( 1 ): 10-14. 被引量:1
  • 3Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommen- dations of the International Working Group for diagnosis, stan- dardization of response criteria, treatment outcomes, and report- ing standards for therapeutic trials in acute myeloid leukemia EJ]. J Clin Oncol, 2003, 21 (24):4642-4649. 被引量:1
  • 4Cheson BD, Greenberg PL, Bennett JM, et al. Clinical applica- tion and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J]. Blood, 2006, 108(2):419-425. 被引量:1
  • 5Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastie syndromes: the alternative dosing for out- patient treatment (ADOPT) trial [J]. J Clin Oncol, 2009, 27(23):3842-3848. 被引量:1
  • 6Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia [J]. Am J Hematol, 2009, 84 (9) :599-600. 被引量:1
  • 7Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study ofepigen- etic priming with decitabine prior to standard induction chemo- therapy for patients with AML[J]. Blood, 2011, 118(6):1472- 1480. 被引量:1
  • 8Song LX, Xu L, Li X, et al. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia[J]. Ann Hematol, 2012, 91 (12): 1879-1886. 被引量:1
  • 9Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines IJ]. Clin Cancer Res, 2007, 13( 14):4225-4232. 被引量:1
  • 10Qian S, Duan L. Effect of low-dose cytarabine and aclarubicin in combination with decitabine on the outcome of patients with high-risk myelodysplastic syndromes [G]. 12^th International Symposium on Myelodysplastie Syndromes. Berlin, Germany: Leukemia Research, 2013: S 152-S 153. 被引量:1

共引文献262

同被引文献135

引证文献21

二级引证文献13

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈